{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:43:12Z","timestamp":1788964992850,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10549-026-07963-z","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:35:00Z","timestamp":1777955700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term outcomes in triple-negative breast cancer after a pathologic complete response: does the type of neoadjuvant therapy matter?"],"prefix":"10.1007","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4312-4172","authenticated-orcid":false,"given":"Lis Vict\u00f3ria","family":"Ravani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth A.","family":"Wander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romualdo","family":"Barroso-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Lustberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Bines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Michelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daxuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Colombo Bonadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"issue":"6","key":"7963_CR1","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","volume":"21","author":"WJ Gradishar","year":"2023","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D et al (2023) NCCN Guidelines\u00ae insights: breast cancer, version 4.2023. J Natl Compr Canc Netw 21(6):594\u2013608. https:\/\/doi.org\/10.6004\/jnccn.2023.0031","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"7963_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061404","volume":"12","author":"JS Lee","year":"2020","unstructured":"Lee JS, Yost SE, Yuan Y (2020) Neoadjuvant treatment for triple negative breast cancer: recent progresses and challenges. Cancers (Basel) 12(6):1404. https:\/\/doi.org\/10.3390\/cancers12061404","journal-title":"Cancers (Basel)"},{"key":"7963_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100332","volume":"21","author":"B Gyawali","year":"2020","unstructured":"Gyawali B, Hey SP, Kesselheim AS (2020) Evaluating the evidence behind the surrogate measures included in the FDA\u2019s table of surrogate endpoints as supporting approval of cancer drugs. EClinicalMedicine 21:100332. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100332","journal-title":"EClinicalMedicine"},{"key":"7963_CR4","unstructured":"Research C for DE and. Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. FDA; 2020 https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pathological-complete-response-neoadjuvant-treatment-high-risk-early-stage-breast-cancer-use"},{"issue":"9938","key":"7963_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164\u2013172. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8","journal-title":"Lancet"},{"issue":"17","key":"7963_CR6","doi-asserted-by":"publisher","first-page":"LBA502","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA502","volume":"42","author":"J Sohn","year":"2024","unstructured":"Sohn J, Kim GM, Jung KH, Jeung HC, Lee J, Lee KS et al (2024) A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial. J Clin Oncol 42(17):LBA502\u2013LBA502. https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA502","journal-title":"J Clin Oncol"},{"issue":"5","key":"7963_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","volume":"35","author":"L Pusztai","year":"2024","unstructured":"Pusztai L, Denkert C, O\u2019Shaughnessy J, Cortes J, Dent R, McArthur H et al (2024) Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Ann Oncol 35(5):429\u2013436. https:\/\/doi.org\/10.1016\/j.annonc.2024.02.002","journal-title":"Ann Oncol"},{"key":"7963_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"7963_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD et al (2011) The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"7963_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"1","key":"7963_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ (2021) IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol 21(1):111. https:\/\/doi.org\/10.1186\/s12874-021-01308-8","journal-title":"BMC Med Res Methodol"},{"issue":"19","key":"7963_CR12","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1002\/sim.3623","volume":"28","author":"M Schemper","year":"2009","unstructured":"Schemper M, Wakounig S, Heinze G (2009) The estimation of average hazard ratios by weighted Cox regression. Stat Med 28(19):2473\u20132489. https:\/\/doi.org\/10.1002\/sim.3623","journal-title":"Stat Med"},{"key":"7963_CR13","doi-asserted-by":"crossref","unstructured":"Geyer C, (2024) GS3\u201305: NSABP B-59\/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer. Presented at: San Antonio Breast Cancer Conference; San Antonio, TX GS3\u201305","DOI":"10.1158\/1557-3265.SABCS24-GS3-05"},{"issue":"11","key":"7963_CR14","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","volume":"33","author":"S Loibl","year":"2022","unstructured":"Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU et al (2022) Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 33(11):1149\u20131158. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1940","journal-title":"Ann Oncol"},{"key":"7963_CR15","doi-asserted-by":"publisher","first-page":"S1257","DOI":"10.1016\/j.annonc.2023.10.008","volume":"34","author":"P Schmid","year":"2023","unstructured":"Schmid P, Cort\u00e9s J, Dent RA, Pusztai L, McArthur HL, Kummel S et al (2023) LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study. Ann Oncol 34:S1257. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.008","journal-title":"Ann Oncol"},{"key":"7963_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S et al (2024) Overall survival with Pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2409932","journal-title":"N Engl J Med"},{"key":"7963_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101571","author":"C Barrios","year":"2023","unstructured":"Barrios C, Harbeck N, Zhang HA, Saji S, Jung KH, Hegg R et al (2023) LBA1 final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC). ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101571","journal-title":"ESMO Open"},{"issue":"5","key":"7963_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","volume":"6","author":"R Nanda","year":"2020","unstructured":"Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A et al (2020) Effect of Pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: An analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol 6(5):676\u2013684. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6650","journal-title":"JAMA Oncol"},{"issue":"12","key":"7963_CR19","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1200\/JCO.21.01506","volume":"40","author":"JH Shepherd","year":"2022","unstructured":"Shepherd JH, Ballman K, Polley MYC, Campbell JD, Fan C, Selitsky S et al (2022) CALGB 40603 (Alliance): Long-Term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without Carboplatin and Bevacizumab in triple-negative breast cancer. J Clin Oncol 40(12):1323\u20131334. https:\/\/doi.org\/10.1200\/JCO.21.01506","journal-title":"J Clin Oncol"},{"key":"7963_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103478","author":"S Loibl","year":"2024","unstructured":"Loibl S, Reinisch M, Just M, Untch M, Stoetzer OJ, Schneeweiss A et al (2024) LBA1 Denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy in patients with primary breast cancer: Time to event analysis from the GeparX 2 \u00d7 2 randomized clinical trial. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103478","journal-title":"ESMO Open"},{"issue":"5","key":"7963_CR21","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-GS5-01","volume":"83","author":"S Gupta","year":"2023","unstructured":"Gupta S, Nair NS, Hawaldar R, Vanmali V, Parmar V, Gulia S et al (2023) Abstract GS5-01: addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: a phase III randomized controlled trial. Cancer Res 83(5):GS5-01. https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-GS5-01","journal-title":"Cancer Res"},{"issue":"8014","key":"7963_CR22","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41586-024-07384-2","volume":"629","author":"JE Abraham","year":"2024","unstructured":"Abraham JE, Pinilla K, Dayimu A, Grybowicz L, Demiris N, Harvey C et al (2024) The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature 629(8014):1142\u20131148. https:\/\/doi.org\/10.1038\/s41586-024-07384-2","journal-title":"Nature"},{"issue":"1","key":"7963_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03474-0","volume":"22","author":"C Wang","year":"2024","unstructured":"Wang C, Yuan L, Wu X, Wang Y, Tian H, Zhang G et al (2024) Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study. BMC Med 22(1):252. https:\/\/doi.org\/10.1186\/s12916-024-03474-0","journal-title":"BMC Med"},{"issue":"22","key":"7963_CR24","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1158\/1078-0432.CCR-22-0482","volume":"28","author":"O Gluz","year":"2022","unstructured":"Gluz O, Nitz U, Kolberg-Liedtke C, Prat A, Christgen M, Kuemmel S et al (2022) De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): impact of molecular markers and final survival analysis of the WSG-ADAPT-TN trial. Clin Cancer Res 28(22):4995\u20135003. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0482","journal-title":"Clin Cancer Res"},{"key":"7963_CR25","doi-asserted-by":"publisher","first-page":"S1258","DOI":"10.1016\/j.annonc.2023.10.009","volume":"34","author":"L Gianni","year":"2023","unstructured":"Gianni L, Huang C, Egle D, Bermejo B, Zamagni C, Thill M et al (2023) LBA19 event-free survival (EFS) analysis of neoadjuvant taxane\/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. Ann Oncol 34:S1258\u2013S1259. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.009","journal-title":"Ann Oncol"},{"issue":"4","key":"7963_CR26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/ijc.33830","volume":"150","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wu ZY, Li J, Lin Y, Liu Z, Cao Y et al (2022) Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label phase II trial. Int J Cancer 150(4):654\u2013662. https:\/\/doi.org\/10.1002\/ijc.33830","journal-title":"Int J Cancer"},{"issue":"4","key":"7963_CR27","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1158\/1078-0432.CCR-20-3646","volume":"27","author":"P Sharma","year":"2021","unstructured":"Sharma P, Kimler BF, O\u2019Dea A, Nye L, Wang YY, Yoder R et al (2021) Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP). Clin Cancer Res 27(4):975\u2013982. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3646","journal-title":"Clin Cancer Res"},{"issue":"3","key":"7963_CR28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10549-020-05580-y","volume":"180","author":"M Iwase","year":"2020","unstructured":"Iwase M, Ando M, Aogi K, Aruga T, Inoue K, Shimomura A et al (2020) Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Res Treat 180(3):687\u2013694. https:\/\/doi.org\/10.1007\/s10549-020-05580-y","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"7963_CR29","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1158\/1078-0432.CCR-22-0862","volume":"28","author":"J Foldi","year":"2022","unstructured":"Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N et al (2022) Clinical outcomes and immune markers by race in a phase I\/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC. Clin Cancer Res 28(17):3720\u20133728. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0862","journal-title":"Clin Cancer Res"},{"issue":"2","key":"7963_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","volume":"10","author":"P Sharma","year":"2024","unstructured":"Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O\u2019Dea A et al (2024) Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol 10(2):227\u2013235. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5033","journal-title":"JAMA Oncol"},{"issue":"10","key":"7963_CR31","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamaoncol.2024.3456","volume":"10","author":"G Villacampa","year":"2024","unstructured":"Villacampa G, Navarro V, Matikas A, Ribeiro JM, Schettini F, Tolosa P et al (2024) Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: a systematic review and meta-analysis. JAMA Oncol 10(10):1331\u20131341. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3456","journal-title":"JAMA Oncol"},{"issue":"22","key":"7963_CR32","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379(22):2108\u20132121. https:\/\/doi.org\/10.1056\/NEJMoa1809615","journal-title":"N Engl J Med"},{"issue":"24","key":"7963_CR33","doi-asserted-by":"publisher","first-page":"04061","DOI":"10.1016\/j.annonc.2024.10.012","volume":"7534","author":"M Mart\u00edn","year":"2024","unstructured":"Mart\u00edn M, Stecklein SR, Gluz O, Villacampa G, Monte-Mill\u00e1n M, Nitz U et al (2024) TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy. Ann Oncol 7534(24):04061\u201304064. https:\/\/doi.org\/10.1016\/j.annonc.2024.10.012","journal-title":"Ann Oncol"},{"key":"7963_CR34","unstructured":"Circulating tumor DNA (ctDNA) to predict response to neoadjuvant chemotherapy (NAC) and prognosis in patients (pts) with early breast cancer (BC) - Record details - Embase [Internet]. (2024) https:\/\/www.embase.com\/records?subaction=viewrecord&rid=7&page=1&id=L644908562"},{"issue":"11","key":"7963_CR35","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1038\/s41591-024-03249-3","volume":"30","author":"I Nederlof","year":"2024","unstructured":"Nederlof I, Isaeva OI, de Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL et al (2024) Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial. Nat Med 30(11):3223\u20133235. https:\/\/doi.org\/10.1038\/s41591-024-03249-3","journal-title":"Nat Med"},{"issue":"2","key":"7963_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM et al (2021) Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol 32(2):229\u2013239. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.007","journal-title":"Ann Oncol"},{"issue":"31","key":"7963_CR37","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1080\/14796694.2024.2357534","volume":"20","author":"SM Tolaney","year":"2024","unstructured":"Tolaney SM, DeMichele A, Takano T, Rugo HS, Perou C, Lynce F et al (2024) OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (\u00b1 capecitabine) for residual triple-negative breast cancer. Future Oncol 20(31):2343\u20132355. https:\/\/doi.org\/10.1080\/14796694.2024.2357534","journal-title":"Future Oncol"},{"issue":"17","key":"7963_CR38","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1200\/JCO.22.02575","volume":"41","author":"GV Long","year":"2023","unstructured":"Long GV, Menzies AM, Scolyer RA (2023) Neoadjuvant checkpoint immunotherapy and melanoma: the time is now. J Clin Oncol 41(17):3236\u20133248. https:\/\/doi.org\/10.1200\/JCO.22.02575","journal-title":"J Clin Oncol"},{"issue":"3","key":"7963_CR39","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.athoracsur.2024.01.004","volume":"118","author":"RS Martins","year":"2024","unstructured":"Martins RS, Razi SS, Alnajar A, Poulikidis K, Latif MJ, Luo J et al (2024) Neoadjuvant vs adjuvant chemoimmunotherapy for stage II-IIIB non-small cell lung cancer. Ann Thorac Surg 118(3):672\u2013681. https:\/\/doi.org\/10.1016\/j.athoracsur.2024.01.004","journal-title":"Ann Thorac Surg"},{"issue":"9","key":"7963_CR40","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR et al (2023) Neoadjuvant-adjuvant or adjuvant-only Pembrolizumab in advanced melanoma. N Engl J Med 388(9):813\u2013823. https:\/\/doi.org\/10.1056\/NEJMoa2211437","journal-title":"N Engl J Med"},{"issue":"18","key":"7963_CR41","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M et al (2024) Neoadjuvant Nivolumab and Ipilimumab in resectable Stage III melanoma. N Engl J Med 391(18):1696\u20131708. https:\/\/doi.org\/10.1056\/NEJMoa2402604","journal-title":"N Engl J Med"},{"key":"7963_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113952","author":"H McArthur","year":"2024","unstructured":"McArthur H, Bailey A, Saji S, El-Abed S, Marta GN, Metzger O et al (2024) Adjuvant chemotherapy with or without Atezolizumab for Stage II and III triple-negative breast cancer: final analysis of the ALEXANDRA\/ IMpassion030 phase 3 trial. Eur J Cancer. https:\/\/doi.org\/10.1016\/j.ejca.2024.113952","journal-title":"Eur J Cancer"},{"key":"7963_CR43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA500","author":"MV Dieci","year":"2024","unstructured":"Dieci MV, Bisagni G, Schmid P, Fotia V, Piacentini F, Laurentiis MD et al (2024) A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy. Journal of Clinical Oncology. https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA500","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"7963_CR44","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-PS4-07-04","volume":"32","author":"R Barroso-Sousa","year":"2026","unstructured":"Barroso-Sousa R, Testa L, Mand\u00f3 P, Tavares MC, Nunes NC, Cordoba G et al (2026) Abstract PS4-07-04: rare but resistant: neoadjuvant chemoimmunotherapy in special histological subtypes of triple-negative breast cancer\u2014insights from the Neo-Real\/GBECAM-0123 study. Clin Cancer Res 32(4):PS4-07\u201304. https:\/\/doi.org\/10.1158\/1557-3265.SABCS25-PS4-07-04","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07963-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07963-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07963-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:30:12Z","timestamp":1784017812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07963-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7963"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07963-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"3 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Authors declare no Competing Non-Financial Interests but the following Competing Financial Interests: SAW: Consulting\/Advisory Board: Gilead, Foundation Medicine, Veracyte, Hologic, Eli Lilly, Biovica, Pfizer\/Arvinas, Puma Biotechnology, Novartis, AstraZeneca, Genentech, Regor Therapeutics, Stemline\/Menarini. Education\/Speaking: Eli Lilly, Guardant Health, 2ndMD Institutional Research Support: Genentech, Eli Lilly, Pfizer\/Arvinas, Nuvation Bio, Regor Therapeutics, Sermonix. MK: reports research funding to the institute from BMS, Roche and AstraZeneca\/MedImmune and an advisory role\/speakers\u2019 fee (all compensated to the institute) for Alderaan, BMS, Domain Therapeutics, Medscape, Roche, MSD and Daiichi Sankyo, outside the submitted work. JC: Consulting\/Advisor: Roche, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Lilly, Merck Sharp&Dohme, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Scorpion Therapeutics, Expres2ion Biotechnologies, Jazz Pharmaceuticals, Abbvie, BridgeBio, Biontech, Biocon, Circle Pharma, Delcath Systems, Inc., Hexagon Bio. Honoraria: Roche, Novartis, Eisai, Pfizer, Lilly, Merck Sharp&Dohme, Daiichi Sankyo, Astrazeneca, Gilead, Steamline Therapeutics. Research funding to the Institution: Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH\/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics,Iqvia, Queen Mary University of London. Stock: MAJ3 Capital, Leuko (relative). Travel, accommodation, expenses: Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, Astrazeneca, Gilead, Merck Sharp&Dhome, Steamline Therapeutics.Patents: Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent.Javier Cort\u00e9s Cast\u00e1n, Alejandro Piris Gim\u00e9nez, Violeta Serra Elizalde. WO 2014\/199294 A. ISSUED. Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cort\u00e9s.US 2019\/0338368 A1. JB: Speaker fees and\/or honoraria for consulting or advisory functions: AstraZeneca, Daiichi-Sankyo, Lilly, Gilead, Pfizer, Novartis, MSD, Roche, Knight Pharmaceuticals. Financial support for educational programs and symposia: Roche, Daiichi-Sankyo. LT: Speaker fees and\/or honoraria for consulting or advisory functions: Daiichi-Sankyo, MSD, AstraZeneca, Pfizer, Lilly, Novartis. Financial support for educational programs and symposia: AstraZeneca, Roche, Gilead. Institutional Research grant: Novartis. RBS: Speaker fees and\/or honoraria for consulting or advisory functions: AstraZeneca, Daiichi-Sankyo, Eli Lilly, Gilead, Libbs, Pfizer, Novartis, MSD, and Roche. Financial support for educational programs and symposia: AstraZeneca, Daiichi-Sankyo, Gilead, Eli Lilly, and MSD. Institutional Research grant: AstraZeneca, Daiichi-Sankyo. RCB: Speaker fees and\/or honoraria for consulting or advisory functions: Daiichi-Sankyo, Nestle Health Science, Addium, Gilead, MSD, BMS, AstraZeneca, Ache, Pfizer, Novartis. Financial support for educational programs and symposia: AstraZeneca, Daiichi-Sankyo, MSD, Lilly. Institutional Research grant: Novartis, AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"28"}}